CA2508136A1 - Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition - Google Patents
Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition Download PDFInfo
- Publication number
- CA2508136A1 CA2508136A1 CA002508136A CA2508136A CA2508136A1 CA 2508136 A1 CA2508136 A1 CA 2508136A1 CA 002508136 A CA002508136 A CA 002508136A CA 2508136 A CA2508136 A CA 2508136A CA 2508136 A1 CA2508136 A1 CA 2508136A1
- Authority
- CA
- Canada
- Prior art keywords
- blood concentration
- index
- concentration data
- correlation
- unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012545 processing Methods 0.000 title claims abstract description 164
- 238000000034 method Methods 0.000 title claims description 168
- 239000002131 composite material Substances 0.000 claims abstract description 637
- 239000002207 metabolite Substances 0.000 claims abstract description 376
- 210000004369 blood Anatomy 0.000 claims description 383
- 239000008280 blood Substances 0.000 claims description 383
- 201000010099 disease Diseases 0.000 claims description 251
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 251
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 243
- 238000004364 calculation method Methods 0.000 claims description 168
- 150000001413 amino acids Chemical class 0.000 claims description 164
- 238000004458 analytical method Methods 0.000 claims description 71
- 238000005457 optimization Methods 0.000 claims description 63
- 230000002503 metabolic effect Effects 0.000 claims description 58
- 238000004088 simulation Methods 0.000 claims description 18
- 241000700159 Rattus Species 0.000 description 92
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 81
- 238000010586 diagram Methods 0.000 description 54
- 238000004891 communication Methods 0.000 description 50
- 206010012601 diabetes mellitus Diseases 0.000 description 43
- 230000008569 process Effects 0.000 description 36
- 230000005540 biological transmission Effects 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 31
- 238000011282 treatment Methods 0.000 description 29
- 238000010276 construction Methods 0.000 description 25
- 208000005176 Hepatitis C Diseases 0.000 description 23
- 230000001276 controlling effect Effects 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 238000013459 approach Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000008676 import Effects 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 15
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 13
- 229960003067 cystine Drugs 0.000 description 13
- 235000021590 normal diet Nutrition 0.000 description 13
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 12
- 238000004590 computer program Methods 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 12
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 11
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000002596 correlated effect Effects 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000010365 information processing Effects 0.000 description 10
- 102000014150 Interferons Human genes 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000013918 Apolipoproteins E Human genes 0.000 description 8
- 108010025628 Apolipoproteins E Proteins 0.000 description 8
- 102000002265 Human Growth Hormone Human genes 0.000 description 8
- 108010000521 Human Growth Hormone Proteins 0.000 description 8
- 239000000854 Human Growth Hormone Substances 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 229960004580 glibenclamide Drugs 0.000 description 8
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 8
- 229960000698 nateglinide Drugs 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000011824 transgenic rat model Methods 0.000 description 8
- 208000006454 hepatitis Diseases 0.000 description 7
- 231100000283 hepatitis Toxicity 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 238000005314 correlation function Methods 0.000 description 6
- 238000011813 knockout mouse model Methods 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940026510 theanine Drugs 0.000 description 6
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 5
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 5
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- -1 aromatic amino acids Chemical class 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 235000020905 low-protein-diet Nutrition 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000002705 metabolomic analysis Methods 0.000 description 4
- 230000001431 metabolomic effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 241001500351 Influenzavirus A Species 0.000 description 3
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000009790 rate-determining step (RDS) Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 2
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 2
- 125000000635 L-ornithyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 2
- 102100027441 Nucleobindin-2 Human genes 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 231100000627 threshold limit value Toxicity 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 0 CCC(*)C(C(C(*)CI)(NC(C*)I)O)O Chemical compound CCC(*)C(C(C(*)CI)(NC(C*)I)O)O 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008867 communication pathway Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 239000011676 menaquinone-4 Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/20—Heterogeneous data integration
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioethics (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002637250A CA2637250A1 (en) | 2002-12-09 | 2003-12-09 | Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-357042 | 2002-12-09 | ||
| JP2002357042 | 2002-12-09 | ||
| JP2003-205589 | 2003-08-01 | ||
| JP2003205589 | 2003-08-01 | ||
| PCT/JP2003/015713 WO2004052191A1 (ja) | 2002-12-09 | 2003-12-09 | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002637250A Division CA2637250A1 (en) | 2002-12-09 | 2003-12-09 | Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2508136A1 true CA2508136A1 (en) | 2004-06-24 |
Family
ID=32510622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002508136A Abandoned CA2508136A1 (en) | 2002-12-09 | 2003-12-09 | Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition |
| CA002637250A Abandoned CA2637250A1 (en) | 2002-12-09 | 2003-12-09 | Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002637250A Abandoned CA2637250A1 (en) | 2002-12-09 | 2003-12-09 | Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8234075B2 (https=) |
| EP (2) | EP2357581A3 (https=) |
| JP (3) | JP4581994B2 (https=) |
| KR (1) | KR100686910B1 (https=) |
| AU (1) | AU2003289263A1 (https=) |
| CA (2) | CA2508136A1 (https=) |
| WO (1) | WO2004052191A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004052191A1 (ja) * | 2002-12-09 | 2004-06-24 | Ajinomoto Co., Inc. | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 |
| EP1862797A4 (en) * | 2005-03-16 | 2009-09-16 | Ajinomoto Kk | DEVICE, METHOD, SYSTEM AND PROGRAM FOR EVALUATING BIOLOGICAL STATES, DEVICE, METHOD AND PROGRAM FOR GENERATING AN EVALUATION FUNCTION AND RECORDING MEDIUM |
| EP1887362A4 (en) * | 2005-05-30 | 2010-01-27 | Ajinomoto Kk | HEPATHOPATHY EVALUATION APPARATUS, HEPATHOPATHY EVALUATION METHOD, HEPATHOPATHY EVALUATION SYSTEM, HEPATHOPATHY EVALUATION PROGRAM, AND RECORDING MEDIUM |
| US20070016389A1 (en) * | 2005-06-24 | 2007-01-18 | Cetin Ozgen | Method and system for accelerating and improving the history matching of a reservoir simulation model |
| EP1865431A1 (en) * | 2006-06-06 | 2007-12-12 | Waters GmbH | System for managing and analyzing metabolic pathway data |
| JP5470848B2 (ja) * | 2006-08-04 | 2014-04-16 | 味の素株式会社 | 肺癌の評価方法、肺癌評価装置、肺癌評価方法、肺癌評価システム、肺癌評価プログラム、記録媒体、および、情報通信端末装置 |
| WO2008016101A1 (en) | 2006-08-04 | 2008-02-07 | Ajinomoto Co., Inc. | Method for evaluation of stress, stress evaluation apparatus, stress evaluation method, stress evaluation system, stress evaluation program, and recording medium |
| WO2008015929A1 (fr) | 2006-08-04 | 2008-02-07 | Ajinomoto Co., Inc. | procédé d'évaluation de syndrome métabolique, appareil D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, système D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, programme d'évaluation de syndrome métabolique et support d'enregistrement, et proc& |
| WO2008075664A1 (ja) | 2006-12-21 | 2008-06-26 | Ajinomoto Co., Inc. | 癌の評価方法、ならびに癌評価装置、癌評価方法、癌評価システム、癌評価プログラムおよび記録媒体 |
| JP5746810B2 (ja) | 2006-12-21 | 2015-07-08 | 味の素株式会社 | 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体 |
| EP2096439A4 (en) * | 2006-12-21 | 2011-01-05 | Ajinomoto Kk | METHOD FOR ASSESSING COLORECTAL CARCINOMA, COLORECTAL CARCINOMA ASSESSMENT DEVICE, METHOD, SYSTEM, PROGRAM AND RECORDING MEDIUM |
| JP2008203250A (ja) * | 2007-01-24 | 2008-09-04 | Ajinomoto Co Inc | Ｉｂｄの評価方法、ならびにアミノ酸情報処理装置、アミノ酸情報処理方法、アミノ酸情報処理システム、アミノ酸情報処理プログラムおよび記録媒体 |
| JP5016316B2 (ja) * | 2007-01-31 | 2012-09-05 | メディアクロス株式会社 | メタボリックシンドローム血管評価システム |
| JPWO2009001862A1 (ja) * | 2007-06-25 | 2010-08-26 | 味の素株式会社 | 内臓脂肪蓄積の評価方法 |
| EP2209001A4 (en) * | 2007-10-25 | 2010-10-27 | Ajinomoto Kk | METHOD FOR ASSESSING STROKEN GLUCOSE TOLERANCE |
| JPWO2009054351A1 (ja) * | 2007-10-25 | 2011-03-03 | 味の素株式会社 | 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラムおよび記録媒体 |
| CN101960310A (zh) * | 2008-03-04 | 2011-01-26 | 味之素株式会社 | 癌症种类的评价方法 |
| KR101817058B1 (ko) * | 2008-06-20 | 2018-01-11 | 아지노모토 가부시키가이샤 | 여성 생식기암의 평가 방법 |
| KR101821551B1 (ko) | 2008-06-20 | 2018-01-25 | 아지노모토 가부시키가이샤 | 전립선 질환의 평가 방법 |
| WO2010064413A1 (ja) * | 2008-12-01 | 2010-06-10 | 国立大学法人山口大学 | 薬剤の作用・副作用予測システムとそのプログラム |
| WO2013002381A1 (ja) | 2011-06-30 | 2013-01-03 | 味の素株式会社 | 脂肪性肝疾患の評価方法、脂肪性肝疾患評価装置、脂肪性肝疾患評価方法、脂肪性肝疾患評価プログラム、脂肪性肝疾患評価システム、情報通信端末装置、および脂肪性肝疾患の予防・改善物質の探索方法 |
| WO2013005790A1 (ja) * | 2011-07-07 | 2013-01-10 | 味の素株式会社 | 生体酸化の評価方法、生体酸化評価装置、生体酸化評価方法、生体酸化評価プログラム、生体酸化評価システム、情報通信端末装置、および生体酸化の予防・改善物質の探索方法 |
| CN103082993B (zh) * | 2011-10-31 | 2016-01-20 | 国民技术股份有限公司 | 人体生物信息检测系统及其检测方法 |
| JP6270257B2 (ja) * | 2012-01-31 | 2018-01-31 | 味の素株式会社 | 取得方法、心血管イベント評価装置、心血管イベント評価プログラム、心血管イベント評価システムおよび端末装置 |
| CN110133296B (zh) * | 2012-03-18 | 2022-03-25 | 镜株式会社 | 疾病样品分析装置、分析系统及分析方法 |
| WO2013168550A1 (ja) * | 2012-05-11 | 2013-11-14 | 味の素株式会社 | 癌免疫療法の評価方法、癌免疫療法評価装置、癌免疫療法評価プログラム、癌免疫療法評価システムおよび情報通信端末装置 |
| WO2014084290A1 (ja) | 2012-11-27 | 2014-06-05 | 味の素株式会社 | 膵臓癌の評価方法、膵臓癌評価装置、膵臓癌評価方法、膵臓癌評価プログラム、膵臓癌評価システムおよび情報通信端末装置 |
| JP6311705B2 (ja) * | 2013-04-09 | 2018-04-18 | 味の素株式会社 | 取得方法、算出方法、インスリン評価装置、算出装置、インスリン評価プログラム、算出プログラム、インスリン評価システム、および端末装置 |
| KR102614827B1 (ko) | 2014-10-08 | 2023-12-19 | 아지노모토 가부시키가이샤 | 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치 |
| JP6886241B2 (ja) * | 2016-01-07 | 2021-06-16 | 味の素株式会社 | 骨格筋面積の評価方法 |
| US10235431B2 (en) * | 2016-01-29 | 2019-03-19 | Splunk Inc. | Optimizing index file sizes based on indexed data storage conditions |
| CA3029144A1 (en) | 2016-06-30 | 2018-01-04 | Ajinomoto Co., Inc. | Evaluating method of ketosis in postpartum dairy cows |
| WO2018066621A1 (ja) | 2016-10-04 | 2018-04-12 | 味の素株式会社 | 大腸癌の評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
| JPWO2018066620A1 (ja) * | 2016-10-04 | 2019-07-18 | 味の素株式会社 | 膵臓癌の評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
| KR102477319B1 (ko) | 2016-12-01 | 2022-12-15 | 아지노모토 가부시키가이샤 | 암 모니터링의 방법, 산출 방법, 평가 장치, 산출 장치, 평가 프로그램, 산출 프로그램, 평가 시스템, 및 단말 장치 |
| EP3779453A4 (en) * | 2018-04-10 | 2022-01-05 | Ajinomoto Co., Inc. | METHOD, DEVICE AND PROGRAM FOR EVALUATING THE HEALTH AND / OR GROWTH STATUS OF LIVESTOCK |
| WO2020067386A1 (ja) | 2018-09-26 | 2020-04-02 | 味の素株式会社 | 軽度認知障害の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 |
| US12163404B2 (en) | 2019-05-24 | 2024-12-10 | National Oilwell Varco, L.P. | Wellsite monitoring system and method |
| US20210225513A1 (en) * | 2020-01-22 | 2021-07-22 | XY.Health Inc. | Method to Create Digital Twins and use the Same for Causal Associations |
| CN121078973A (zh) | 2023-04-28 | 2025-12-05 | 味之素株式会社 | 分娩后的代谢性疾病的评价方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61126472A (ja) | 1984-11-24 | 1986-06-13 | Advance Res & Dev Co Ltd | 診断方法 |
| KR910002651B1 (ko) * | 1987-11-13 | 1991-04-27 | 스미또모 덴끼 고교 가부시끼가이샤 | 간 기능 검사 장치 |
| JPH0620459B2 (ja) * | 1987-11-13 | 1994-03-23 | 住友電気工業株式会社 | 肝機能検査装置 |
| DE69214628T2 (de) | 1991-01-18 | 1997-05-22 | Esa Inc | Verfahren zur Diagnose von Störungen der Körperfunktionen unter Verwendung von biochemischen Pryfilen |
| AU1837495A (en) | 1994-10-13 | 1996-05-06 | Horus Therapeutics, Inc. | Computer assisted methods for diagnosing diseases |
| EP0842475B1 (en) * | 1995-07-25 | 2000-11-08 | Horus Therapeutics, Inc. | Computer assisted methods and apparatus for diagnosing diseases |
| US5687716A (en) * | 1995-11-15 | 1997-11-18 | Kaufmann; Peter | Selective differentiating diagnostic process based on broad data bases |
| US6059724A (en) * | 1997-02-14 | 2000-05-09 | Biosignal, Inc. | System for predicting future health |
| US6300136B1 (en) * | 1997-09-03 | 2001-10-09 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis and treatment of tumors in humans |
| US20040022827A1 (en) * | 1997-09-30 | 2004-02-05 | Chugai Seiyaku Kabusiki Kaisha | Remedy for hepatopathy |
| JPH11190734A (ja) | 1997-12-26 | 1999-07-13 | Wakamoto Pharmaceut Co Ltd | クローン病の検査方法および検査用キット |
| EP1224564A1 (en) | 1999-04-26 | 2002-07-24 | Surromed, Inc. | Phenotype and biological marker identification system |
| EP1228370A2 (en) * | 1999-11-10 | 2002-08-07 | Structural Bioinformatics Inc. | Computationally derived protein structures in pharmacogenomics |
| US20020009740A1 (en) | 2000-04-14 | 2002-01-24 | Rima Kaddurah-Daouk | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| EP1283024B1 (en) * | 2000-04-18 | 2009-03-25 | Yamato Scale Co., Ltd. | Visceral fat meter |
| EP1386275A2 (en) * | 2000-07-18 | 2004-02-04 | Correlogic Systems, Inc. | A process for discriminating between biological states based on hidden patterns from biological data |
| JP4545899B2 (ja) | 2000-07-31 | 2010-09-15 | キヤノン株式会社 | 加熱装置および画像形成装置 |
| US6631330B1 (en) * | 2000-08-21 | 2003-10-07 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers |
| WO2002025405A2 (en) * | 2000-09-19 | 2002-03-28 | The Regents Of The University Of California | Methods for classifying high-dimensional biological data |
| JP4315603B2 (ja) * | 2001-01-26 | 2009-08-19 | 東京瓦斯株式会社 | 炎症性腸疾患診断剤 |
| JP3933882B2 (ja) * | 2001-03-30 | 2007-06-20 | 富士通株式会社 | レーダーチャートを表示させるためのプログラムおよびレーダーチャート表示方法 |
| CA2447857A1 (en) * | 2001-05-21 | 2002-11-28 | Parteq Research And Development Innovations | Method for determination of co-occurences of attributes |
| JP2003159095A (ja) | 2001-07-12 | 2003-06-03 | Takeda Chem Ind Ltd | 結合分子予測方法およびその利用方法 |
| WO2003017177A2 (en) * | 2001-08-13 | 2003-02-27 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
| CA2399169A1 (en) * | 2001-09-07 | 2003-03-07 | Queen's University At Kingston | Diagnostic methods for determining susceptibility to convulsive conditions |
| AU2003227237A1 (en) * | 2002-03-29 | 2003-10-13 | Asahi Kasei Pharma Corporation | Method of detecting mild impaired glucose tolerance or insulin hyposecretion |
| JP2004135546A (ja) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | クローン病の疾患マーカー及びその利用 |
| WO2004038602A1 (en) | 2002-10-24 | 2004-05-06 | Warner-Lambert Company, Llc | Integrated spectral data processing, data mining, and modeling system for use in diverse screening and biomarker discovery applications |
| WO2004052191A1 (ja) | 2002-12-09 | 2004-06-24 | Ajinomoto Co., Inc. | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 |
| JP2004321179A (ja) | 2003-04-07 | 2004-11-18 | Nitto Boseki Co Ltd | 炎症性腸疾患診断用マーカー遺伝子もしくは蛋白質およびそれを利用した炎症性腸疾患診断方法 |
| US7064104B2 (en) * | 2003-06-13 | 2006-06-20 | The Procter & Gamble Company | Methods of managing the symptoms of premenstrual syndrome |
| US20060170928A1 (en) * | 2003-12-24 | 2006-08-03 | Vadivel Masilamani | Masila's cancer detector based on optical analysis of body fluids |
| JP4200441B2 (ja) | 2003-08-13 | 2008-12-24 | 財団法人柏戸記念財団 | 臨床検査データの可視化表現シートの作成装置 |
| AU2004267806A1 (en) * | 2003-08-20 | 2005-03-03 | Bg Medicine, Inc. | Methods and systems for profiling biological systems |
| US8346482B2 (en) * | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
| EP1709442A4 (en) | 2003-12-11 | 2010-01-20 | Correlogic Systems Inc | METHOD FOR DIAGNOSING BIOLOGICAL CONDITIONS BY USING A CENTRALIZED ADAPTIVE MODEL AND SAMPLE PREPARATION |
| US7433853B2 (en) * | 2004-07-12 | 2008-10-07 | Cardiac Pacemakers, Inc. | Expert system for patient medical information analysis |
-
2003
- 2003-12-09 WO PCT/JP2003/015713 patent/WO2004052191A1/ja not_active Ceased
- 2003-12-09 EP EP11157821A patent/EP2357581A3/en not_active Withdrawn
- 2003-12-09 AU AU2003289263A patent/AU2003289263A1/en not_active Abandoned
- 2003-12-09 EP EP03777384A patent/EP1570779A4/en not_active Withdrawn
- 2003-12-09 CA CA002508136A patent/CA2508136A1/en not_active Abandoned
- 2003-12-09 CA CA002637250A patent/CA2637250A1/en not_active Abandoned
- 2003-12-09 KR KR1020057010476A patent/KR100686910B1/ko not_active Expired - Lifetime
- 2003-12-09 JP JP2005502361A patent/JP4581994B2/ja not_active Expired - Lifetime
-
2005
- 2005-06-09 US US11/148,352 patent/US8234075B2/en active Active
-
2010
- 2010-07-12 JP JP2010158021A patent/JP5707757B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-30 US US13/483,359 patent/US20120239366A1/en not_active Abandoned
-
2013
- 2013-07-22 JP JP2013152149A patent/JP5971209B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003289263A1 (en) | 2004-06-30 |
| WO2004052191A1 (ja) | 2004-06-24 |
| US8234075B2 (en) | 2012-07-31 |
| JP4581994B2 (ja) | 2010-11-17 |
| CA2637250A1 (en) | 2004-06-24 |
| JP5707757B2 (ja) | 2015-04-30 |
| KR20050084227A (ko) | 2005-08-26 |
| US20120239366A1 (en) | 2012-09-20 |
| JP2013257333A (ja) | 2013-12-26 |
| JPWO2004052191A1 (ja) | 2006-04-06 |
| JP2010281826A (ja) | 2010-12-16 |
| JP5971209B2 (ja) | 2016-08-17 |
| EP1570779A4 (en) | 2008-03-12 |
| EP1570779A1 (en) | 2005-09-07 |
| EP2357581A2 (en) | 2011-08-17 |
| EP2357581A3 (en) | 2012-09-12 |
| KR100686910B1 (ko) | 2007-02-26 |
| US20050283347A1 (en) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1570779A1 (en) | Organism condition information processor, organism condition information processing method, organism condition information managing system, program, and recording medium | |
| Liu et al. | Computationally optimized SARS-CoV-2 MHC class I and II vaccine formulations predicted to target human haplotype distributions | |
| EP2365456B1 (en) | Data structure, method and system for predicting medical conditions | |
| Waters | Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base | |
| EP1862797A1 (en) | Biocondition evaluating device, biocondition evaluating method, biocondition evaluating system, biocondition evaluating program, evaluation function generating device, evaluation function generating method, evaluation function generating program, and recording medium | |
| US20020019746A1 (en) | Aggregating persons with a select profile for further medical characterization | |
| Kimura et al. | Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks | |
| CN1748217A (zh) | 增强计算机辅助医疗数据处理系统及方法 | |
| CN1748218A (zh) | 综合医疗知识库界面系统及方法 | |
| WO2002064826A2 (en) | Network for evaluating data obtained in a biochip measurement device | |
| Yuan et al. | Predicting the solvent accessibility of transmembrane residues from protein sequence | |
| Lopez et al. | Using EMBL‐EBI services via web interface and programmatically via web services | |
| Kang et al. | Disease specific ontology of adverse events: Ontology extension and adaptation for chronic kidney disease | |
| CN100502763C (zh) | 生物体状态信息处理装置和其方法、以及生物体状态信息管理系统 | |
| CODATA Task Group on Biological Macromolecules and Colleagues | Quality control in databanks for molecular biology | |
| Pan et al. | Characterization of a ligand− receptor binding event using receptor-dependent four-dimensional quantitative structure− activity relationship analysis | |
| US20040254737A1 (en) | Information processing apparatus, information processing method, storage medium and program | |
| MXPA06011525A (es) | Sistema y metodos para manejo del tratamiento y datos del paciente. | |
| Tong et al. | Computer-aided vaccine design | |
| Adl et al. | Feature ranking based on synergy networks to identify prognostic markers in DPT-1 | |
| Mitchell et al. | Social disparities in thoracic surgery database research: implications and impact | |
| JP7729341B2 (ja) | 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 | |
| JP4362290B2 (ja) | ハプロタイプ解析装置、および、ハプロタイプ解析方法をコンピュータに実行させることを特徴とするプログラム | |
| JP2004357552A (ja) | 作用物質による効果推定方法及びスクリーニング方法 | |
| Wang et al. | Using SCDL for integrating tools and data for complex biomedical applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20141209 |